Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × INDUSTRY × mCRPC × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 382 Breast Neoplasms 342 Neoplasms 262 Prostatic Neoplasms 178 Neoplasm Metastasis 138 Multiple Myeloma 125 Colorectal Neoplasms 106 Ovarian Neoplasms 92 Lung Neoplasms 92 Parkinson Disease 4, Autosomal Dominant Lewy Body 87 Lymphoma, Follicular 84 Melanoma 80 Recurrence 78 Carcinoma, Hepatocellular 76 Lymphoma, Non-Hodgkin 75 Papillomavirus Infections 74 Leukemia, Lymphocytic, Chronic, B-Cell 71 Leukemia, Myeloid, Acute 66 Small Cell Lung Carcinoma 64 Stomach Neoplasms 62 Pain 61 Carcinoma, Renal Cell 60 Uterine Cervical Neoplasms 58 Pancreatic Neoplasms 58 Keratosis, Actinic 57 Urinary Bladder Neoplasms 50 Lymphoma, Large B-Cell, Diffuse 49 Myasthenia Gravis 46 Carcinoma 46 Leiomyoma 43

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡